. 2008 Nov 6;7:83. doi: 10.1186/1476-4598-7-83

Table 3.

Univariate survival analysis of clinicopathological and immunohistochemical parameters with SFRP2 promoter methylation

	Disease-free survival (DFS)			Overall survival (OS)

Variable	n^a	Events	P^b	n^a	Events	P^b
*Clinicopathological factors*

Age at diagnosis
< 60 years	84	33	0.391	83	15	0.414
≥ 60 years	52	18		53	13

Tumor size^c
pT1	51	16	0.059	51	8	0.165
pT2 – 4	82	35		82	20

Lymph node status^c
pN0	59	15	0.008	59	7	0.026
pN1 – 3	66	31		66	18

Histological grade
G1 – G2	72	19	0.003	73	7	0.001
G3	61	32		61	21

Histological type
ductal	109	35	0.009	109	25	0.622
lobular	18	9		18	2
other	9	7		9	1

*Immunohistochemistry*

Estrogen receptor
negative (IRS^d0 – 2)	47	16	0.644	46	12	0.118
positive (IRS 3 – 12)	84	35		85	16

Progesterone receptor
negative (IRS^d0 – 2)	44	19	0.318	45	12	0.093
positive (IRS 3 – 12)	87	32		86	16

*SFRP2 promoter*

unmethylated	23	5	0.192	23	5	0.686
methylated	113	45		113	23

^aOnly female patients with primary, unilateral, invasive breast cancer were included. ^bUnivariate log-rank test (two-sided). ^cAccording to UICC: TNM Classification of Malignant Tumours [38]. ^dIRS = immunoreactivity score [40]. Significant P-values marked in bold face.